We serve Chemical Name:3,5-DICHLOROPHENYLZINC IODIDE CAS:312692-86-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3,5-DICHLOROPHENYLZINC IODIDE
CAS.NO:312692-86-7
Synonyms:3,5-DICHLOROPHENYLZINC IODIDE
Molecular Formula:C6H3Cl2IZn
Molecular Weight:338.29
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.002 g/mL at 25 °C
Index of Refraction:
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2056 3/PG 2
Packing Group:
Contact us for information like 3,5-DICHLOROPHENYLZINC IODIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,5-DICHLOROPHENYLZINC IODIDE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-DICHLOROPHENYLZINC IODIDE Use and application,3,5-DICHLOROPHENYLZINC IODIDE technical grade,usp/ep/jp grade.
Related News: This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 3,5-DICHLOROPHENYLZINC IODIDE manufacturer Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. 3,5-DICHLOROPHENYLZINC IODIDE supplier A week after the memo was released to employees, Reuters reported that the Justice Department had launched a criminal investigation focused on the Branchburg plant. That same day, May 27, Lilly reported to the U.S. Securities and Exchange Commission that it had received a subpoena from the department seeking documents related to the factory. 3,5-DICHLOROPHENYLZINC IODIDE vendor A week after the memo was released to employees, Reuters reported that the Justice Department had launched a criminal investigation focused on the Branchburg plant. That same day, May 27, Lilly reported to the U.S. Securities and Exchange Commission that it had received a subpoena from the department seeking documents related to the factory. 3,5-DICHLOROPHENYLZINC IODIDE factory This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved.
